The latest price target for TG Therapeutics (NASDAQ:TGTX) was reported by HC Wainwright & Co. on September 18, 2024. The analyst firm set a price target for $49.00 expecting TGTX to rise to within 12 months (a possible 92.95% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for TG Therapeutics (NASDAQ:TGTX) was provided by HC Wainwright & Co., and TG Therapeutics reiterated their buy rating.

The last upgrade for TG Therapeutics Inc happened on August 2, 2023 when Goldman Sachs raised their price target to $12. Goldman Sachs previously had a sell for TG Therapeutics Inc.

The last downgrade for TG Therapeutics Inc happened on November 15, 2021 when Goldman Sachs changed their price target from $33 to $26 for TG Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TG Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TG Therapeutics was filed on September 18, 2024 so you should expect the next rating to be made available sometime around September 18, 2025.

While ratings are subjective and will change, the latest TG Therapeutics (TGTX) rating was a reiterated with a price target of $49.00 to $49.00. The current price TG Therapeutics (TGTX) is trading at is $25.40, which is out of the analyst’s predicted range.